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Abstract
Background Farnesyltransferase inhibitor tipifarnib
(R115777) has been used for treatment of hematological
malignancies; however, its observed anticancer effect was
limited. This prompted us to search for inhibitors that would
show synergic, proapoptotic effect when combined with
R115777.WedecidedtostudyLY294002,whichinhibitsPI-3
kinase, and tanespimycin (17AAG), which inhibits Hsp90—a
chaperone for a number of proteins, including Akt kinase.
Methods The effect of drugs, used alone or in combina-
tion, was tested in U937 cells (human leukemic monocyte
lymphoma), which are often used as a model for liquid
tumor. The number of viable cells was evaluated with
trypan blue staining, while apoptosis was assessed by
presence of active caspase-3 and terminal dUTP nick-end
labeling of DNA (TUNEL).
Results At concentrations in which R115777, LY294002
and 17AAG were only slowing down the proliferation rate,
when used separately, the combination of R115777 ?
LY294002 and R115777 ? 17AAG signiﬁcantly reduced the
number of cells and induced cellular apoptosis.
Conclusions Our results suggest that the combination of
R115777 ? 17AAG could be useful in treating some of the
hematological malignancies.
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Introduction
About 30–80% of various cancers display Ras activating
mutations that cause increased stimulation of downstream
signaling pathways (Bos 1989). Attachment of the farnesyl
group to the Cys residue in the C-terminal CAAX-box of
Ras enables to anchor this protein to the plasma membrane.
Inhibition of Ras farnesylation causes dislocation of Ras
from the plasma membrane and interrupts its participation
in intracellular signaling (Sebti and Hamilton 1997).
Farnesyltransferase inhibitors (FTI) are a large group of
compounds that were speciﬁcally developed in order to
block the activity of oncogenic Ras in tumor cells, although
it is now clear that Ras mutations are not required for
cancer susceptibility to FTI (Appels et al. 2005; Caraglia
et al. 2005). Geranylgeranylation of RhoB induced by FTI
treatment seems to be important for reduction of cells’
growth and induction of apoptosis (Liu et al. 2000). FTI
treatment also inhibits farnesylation of centromere-associ-
ated proteins CENP-E and CENP-F, which leads to G2/M
arrest of certain tumor cells (Ashar et al. 2000), thus
showing that multiple molecular effectors are behind the
anticancer activity of FTIs.
One of the most intensively studied FTI is tipifarnib
(R115777), which acts as competitive, nonpeptidomimetic
inhibitor of the CAAX-peptide binding site of far-
nesyl:protein transferase. Both in vitro and in vivo studies
have demonstrated that R115777 can display anticancer
activity against different types of tumors, and hematopoi-
etic malignancies in particular (Zujewski et al. 2000; Karp
et al. 2001; Cortes et al. 2003). However, the outcome of
clinical trials was somewhat disappointing, showing that
anticancer activity of R115777 is rather limited (Harous-
seau et al. 2007; Lancet et al. 2007). In vitro studies show
that *10 lM R115777 can induce apoptosis initiated by
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2008). Such concentrations are very difﬁcult to reach in
humans, because when R115777 is administered orally, at
the typical dose of 300–600 mg bid, its maximum plasma
level reaches only *2.5 lM (Zujewski et al. 2000; Karp
et al. 2001). Thus, insufﬁcient concentration of the drug
can partially explain the rather disappointing effects of FTI
monotherapy. Much better anticancer activity was achieved
with combinatorial approaches, when R115777 was used
together with other classical or modern chemotherapeutics
(Zhu et al. 2005; Lancet et al. 2011; Jabbour et al. 2011).
Hsp90 is the most abundant protein in the cell and acts
as chaperone to maintain client proteins in their active
conformation and to protect them against degradation by
proteasome. Hsp90 concentration is further increased in
tumor cells, in response to stress induced by elevated
concentration of oncogenic proteins, which are often
thermodynamically unstable (Mosser and Morimoto 2004;
Whitesell and Lindquist 2005). The list of Hsp90 clients
contains a few hundred proteins that participate in all
crucial aspects of cancer biology, such as uncontrolled
proliferation, protection against apoptosis, angiogenesis
and increased metastasis (Zhao et al. 2005). Examples of
Hsp90 client proteins include growth factor and steroid
hormone receptors, tyrosine and serine/threonine kinases
(e.g. Akt kinase), telomerase, P53 and survivin. Hsp90 has
long represented an attractive target for chemotherapy,
since its inhibition is inﬂuencing simultaneously a whole
range of processes important for cancer development
(Isaacs et al. 2003; Bagatell and Whitesell 2004).
Geldanamycin and its derivative 17-allylamino-17-
demethoxygeldanamycin (tanespimycin; 17AAG) are com-
petitive inhibitors of ATP-binding pocket of Hsp90 that
block its ATPase-dependent chaperone activity (Schulte
and Neckers 1998). 17AAG was used in several clinical
trials as anticancer agent to treat different types of tumors
(Solit et al. 2007; Richardson et al. 2010a). These tests
showed that 17AAG can be safely administered to humans,
but unfortunately, its anticancer activity in monotherapy
was very limited. Much better antitumor effects were
obtained when 17AAG was combined with other modern
chemotherapeutics (Ramalingam et al. 2008; Richardson
et al. 2010b).
It is now generally accepted that multidrug, multitar-
geted strategies are likely to be more successful in ﬁghting
cancer comparing with single drug, single target approa-
ches. In our previous study, we have shown that combi-
nation of drugs that inhibit different signaling pathways
can result in an unexpectedly strong synergistic proapop-
totic effect (Małecki et al. 2010). The above rationale
convinced us to search for drugs that would show syner-
gism in inducing apoptosis in combination with R115777.
Since high concentrations of R115777 induce apoptosis by
stimulating the release of cytochrome c from mitochondria
to cytosol, we decided to test drugs that inhibit the PI-3
kinase/Akt kinase pathway, which suppresses induction of
apoptosis through the intrinsic pathway. First, we tested the
combined effect of R115777 and LY294002, which is a
direct inhibitor of the PI-3 kinase. Next, we used 17AAG
that inhibits Hsp90, and among many other molecular
targets, it indirectly down-regulates the activity of Akt
kinase. Our results show that the proapoptotic activity of
R115777 can be increased by combining it with LY294002
or 17AAG. This is an important ﬁnding, because both
R115777 and 17AAG are registered anticancer drugs, and
therefore, their combination could be implemented in the
near future as part of the strategy to ﬁght hematologic
malignancies.
Materials and methods
Materials
Fluorogenic substrate for caspase-3 (Ac-DEVD-AFC) was
purchased from MP Biomedicals (Solon, OH, USA), Tit-
erTACS In Situ Apoptosis Detection Kit (Colorimetric)
was from R&D Systems (Minneapolis, MN, USA), and
R115777 was from Johnson & Johnson Pharmaceutical
Research and Development (Raritan, NJ, USA). Anti-
cleaved caspase-9 (No. 9505), anti-phospho-ERK1/2 (No.
9101) and anti-phospho-Akt (No. 9271) antibodies were
from Cell Signaling Technology (Danvers, MA, USA), and
anti-Hsp90 (No. 610418) antibody was from BD Biosci-
ences (Mississauga, ON, Canada). Caspase-3 inhibitor
(Ac-DEVD-CHO), 17AAG, LY294002, anti-b-actin (No.
A1978) antibody and other chemicals were from Sigma-
Aldrich (St. Luis, MO, USA).
Cell treatment and quantitation
U937 cells were provided by Polish National Cell Bank
(Wrocław, Poland). Cells were propagated in standard
conditions (37C, 5% CO2) in RPMI-1640 medium sup-
plemented with 10% fetal bovine serum. Cells were seeded
(2–5 9 10
5 cells/ml), treated with inhibitors or vehicle
(0.2% dimethyl sulfoxide (DMSO)) for desired time and
harvested by centrifugation. After washing with PBS, cells
were labeled with trypan blue to visualize dead cells (blue),
and the amount of viable cells (white) were counted. In
proliferation assays, the data were normalized to the initial
viable cell number (100%), that is, number of cells present
at the moment of inhibitor administration. Each experiment
was run at least three times in duplicates. The obtained data
were averaged, and the standard deviation is represented in
graphs by bars.
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The inhibitory concentration 50% (IC50) was determined
based on relation between the number of viable cells and
the inhibitor concentration, using the following formula
(Eq. 1):
V ¼
Vmax   IC50
IC50 þ½ S 
ð1Þ
where V is the normalized cells viability, Vmax is the
maximum normalized cells viability, and [S] is the inhib-
itor concentration. The standard error of estimated IC50 is
given with 95% conﬁdence limit.
Evaluation of caspase-3 activity
Cells were seeded, incubated with inhibitors for indicated
time, harvested and counted. Equal amount of cells were
lysed in lysis buffer: 50 mM Tris–HCl, pH 7.6, 100 mM
NaCl, 1 mM EDTA, 1% Triton X-100, and assayed for
activity of caspase-3 (DEVD-like caspase activity) as in
Małecki et al. (2010). The amount of aminoﬂuorocumarin
(AFC) released during incubation with Ac-DEVD-AFC
were measured using spectroﬂuorimeter. For clarity of
presentation, the measured ﬂuorescence intensity values
were normalized to value obtained in control (cells treated
with DMSO) and expressed as fold increase in DEVD-like
caspase activity. Each experiment was run at least three
times in triplicates. The obtained data were averaged, and
the standard deviation is represented in graphs by bars.
TUNEL-based detection of apoptosis
Apoptosis was evaluated by terminal dUTP nick-end
labeling (TUNEL) assay using TiterTACS In Situ Apop-
tosis Detection Kit (Colorimetric) from R&D Systems.
Cells were seeded and incubated with inhibitors for indi-
cated time, ﬁxed and counted. Equal amount of cells
(*10
5) were nick-end labeled following the manufac-
turer’s protocol. The absorbance at 450 nm (A450nm), cor-
responding to the amount of nick-ends, was measured. For
clarity of presentation, the A450nm values were normalized
to value obtained in control (cells treated with DMSO) and
expressed as fold increase of A450nm/cell number. Each
experiment was run at least two times in triplicates. The
obtained data were averaged, and the standard deviation is
represented in graphs by bars.
Western blotting
The relative amount of cleaved caspase-9, phospho-ERK1/
2 and phospho-Akt was determined by western blot-
ting using the appropriate antibodies. Anti-b-actin or
anti-Hsp90 antibodies were used to check for equal load-
ing. Each experiment was repeated three times with similar
results. One representative experiment is shown.
Results
Tipifarnib (R115777) has been used previously to treat
some hematological malignancies but with limited success.
We decided to test its effect on U937 cells (human leu-
kemic monocyte lymphoma cell line), which are frequently
used as a model for liquid tumor and antitumor testing.
Cells were seeded, treated with increasing concentrations
of R115777 for 24 h and stained with trypan blue, and the
number of viable cells was counted. The results were
normalized to the initial (100%) viable cell number.
Results in Fig. 1a show decrease in the number of viable
cells with increasing concentration of R115777. The
number of viable cells was reduced below their initial level
when R115777 was present at concentration higher than
*5 lM. Same data were also plotted as: number of viable
cells versus inhibitor concentration (Fig. 1b) and used to
estimate the IC50 value, which was 3.3 ± 0.3 lM.
Reduction in cell number could result from apoptotic
death, and so we measured the activity of caspase-3 in cells
exposed to increasing concentrations of R115777 (Fig. 2a).
For concentrations lower than IC50, the activity of caspase-
3 was only slightly elevated, while it increased consider-
ably at higher inhibitor concentrations. This indicates that
at lower concentrations, R115777 acted mainly by slowing
down the proliferation rate, while at higher concentrations,
the inhibitor very likely induced apoptosis. Further exper-
iments showed that incubation with 10 lM R115777
induced cleavage of caspase-9 (Fig. 2b) and at the same
time reduced the level of phosphorylation of Akt and ERK
1/2. The apoptosis was conﬁrmed with results obtained
from TUNEL (Fig. 2c). Treatment of U937 cells with
10 lM R115777 for 48 h increased the amount of DNA
nick-ends over 10 times, with respect to control cells.
Although 10 lM R115777 induces apoptotic death in
U937 cells, it is unlikely that this drug can reach such a
concentration in human plasma, since its oral administra-
tion at typical doses gives a maximum plasma concentra-
tion of up to *2.5 lM (Zujewski et al. 2000; Karp et al.
2001). On the other hand, R115777 at concentrations below
IC50 (e.g. 2.5 lM) was not inducing apoptosis to large
extent (Fig. 2a; see also Figs. 3c, 4c later in the text). This
suggests that at low concentrations, R115777 is just
slowing down the proliferation rate, which can partly
explain its limited success in clinical trials. Such obser-
vation prompted us to test R115777 in combination with
other inhibitors in hope to ﬁnd a combination that would
synergize in inducing apoptosis.
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123Since R115777 reduced the level of Akt phosphoryla-
tion (Fig. 2b), the ﬁrst choice was to use LY294002 to
inhibit the PI3-kinase/Akt kinase pathway, which protects
cells against apoptosis initiated by the intrinsic pathway.
Initially, the effect of increasing concentration of
LY294002 on the proliferation rate was tested. Results in
Fig. 3a show the decrease in the number of viable cells
with increasing concentration of LY294002. The number
of viable cells was reduced below their initial amount when
LY294002 was present at concentration higher than
*10 lM. The estimated IC50 was 6.3 ± 0.8 lM.
Next, cells were treated with the combination of
R115777 and LY294002. Both inhibitors were used at
concentrations below their IC50 values, so that when used
individually, they were mainly slowing down the prolif-
eration without actually reducing the number of viable cells
below their initial amount (Fig. 3b). Interestingly, 24-h
incubation with the combination of 2.5 lM R115777 ?
5 lM LY294002 was able to reduce the number of viable
cells to *50% of their initial amount.
Parallel experiments showed that after 48-h incubation
with the combination of 2.5 lM R115777 ? 5 lM
Fig. 1 R115777 reduces the number of U937 cells. a Cells were
incubated for 24 h with increasing concentrations of R115777 and
stained with trypan blue, and the number of viable cells was counted.
The amount of cells were expressed as % of initial viable cell number
(number of viable cells present at the moment of R115777
administration was set as 100%). b Data from (a) were plotted as:
number of viable cells versus inhibitor concentration and used to
estimate the IC50 value. Solid line represents the best ﬁt of data to
Eq. 1. Dashed line shows the initial number of viable cells, present at
the moment of R115777 administration
Fig. 2 R115777 induces apoptosis in U937 cells. a Cells were
incubated for 24 h with increasing concentration of R115777 and
counted. Equal amount of cells were collected, lysed and assayed for
DEVD-like caspase activity as in ‘‘Materials and methods.’’ Data
were expressed as fold increase in DEVD-like caspase activity
relative to control. b Cells were incubated for 48 h in the absence or
presence of 10 lM R115777, lysed and analyzed by Western blotting
using indicated antibodies. Anti-b-actin was used to show equal
loading. c Cells were treated for 48 h with DMSO or 10 lM
R115777. Next, cells were ﬁxed and counted. Equal amount of cells
were subjected to TUNEL as in ‘‘Materials and methods.’’ The
amount of DNA nick-ends (A450nm) were expressed as fold increase
relative to control
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over 10 times with respect to control (Fig. 3c), while
incubation with individual inhibitors did not cause sub-
stantial increase in TUNEL signal. This demonstrates that
R115777 and LY294002 exhibit synergism in inducing
apoptosis in U937 cells, while the individual inhibitors,
when used at concentrations below IC50, do not cause
apoptosis, but act mainly by decreasing the proliferation
rate.
In U937 cells, 5 lM LY294002 reduced the phosphory-
lationofAkt,andcombinedactionofR115777 ? LY294002
reduced the phosphorylation of Akt even more, while the
phosphorylation of ERK1/2 remained basically unchanged
(Fig. 3d).
The increased proapoptotic activity of the combination
of R115777 ? LY294002 is an interesting phenomenon,
which is, however, of limited importance to clinical prac-
tice, since LY294002 is known to induce severe liver
toxicity. Therefore, we searched for other inhibitors that
would synergize with R115777 in inducing apoptosis. We
decided to test tanespimycin (17AAG) that is a registered
anticancer drug, and its use was shown to be safe for
humans. Since 17AAG inhibits the chaperone activity of
Hsp90, and Akt is one of the client proteins for Hsp90, one
could expect that 17AAG would inﬂuence the phosphory-
lation status of Akt.
When U937 cells were treated with increasing concen-
tration of 17AAG for 24 h, they responded by decreasing
their apparent proliferation rate (Fig. 4a). At higher con-
centrations, 17AAG was able to reduce viable cell number
below their initial amount. The estimated IC50 value was
54 ± 8 nM.
Next, cells were treated with the combination of
R115777 ? 17AAG. Also in this case, the inhibitors were
used at concentrations that were slightly below their
determined IC50, so that when used individually, they were
Fig. 3 Combination of R115777 ? LY294002 reduces cell number
and induces apoptosis in U937 cells. a Cells were incubated for 24 h
with increasing concentrations of LY294002 and stained with trypan
blue, and the number of viable cells was counted. The amount of cells
were expressed as % of initial viable cell number (number of cells
present at the moment of LY294002 administration was set as 100%).
b Cells were incubated for 24 h in the absence or presence of
indicated concentrations of R115777, LY294002 or R115777 ?
LY294002 and stained with trypan blue, and the number of viable
cells was counted. The amount of viable cells were expressed as in
(a). c Cells were treated for 48 h in the absence or presence of
indicated concentrations of R115777, LY294002 or R115777 ?
LY294002. Next, cells were ﬁxed and counted, and equal amount of
cells were subjected to TUNEL as in ‘‘Materials and methods.’’ The
amount of DNA nick-ends (A450nm) were expressed as fold increase
relative to control. d Cells were incubated for 24 h in the absence or
presence of indicated concentrations of R115777, LY294002, 17AAG
or combination of inhibitors, lysed and analyzed by Western blotting
using indicated antibodies. Anti-Hsp90 was used to show equal
loading
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number of viable cells below their initial amount (Fig. 4b).
After 24-h incubation of cells with the combination of
2.5 lM R115777 ? 50 nM 17AAG, the number of viable
cells was reduced to *65% comparing with their initial
amount.
The combination of R115777 ? 17AAG was also tested
for induction of apoptosis using TUNEL-based assay. The
results in Fig. 4c show that the amount of DNA nick-ends
were considerably increased after incubation with the
combination of R115777 ? 17AAG, but not after incuba-
tion with the individual inhibitors. This shows that at tested
concentrations, the individual inhibitors do not cause
apoptosis but rather act by decreasing the proliferation rate.
Thus, R115777 and 17AAG exhibit synergy in inducing
apoptosis in U937 cells.
In U937 cells, 50 nM 17AAG was able to reduce the
phosphorylation of both Akt and ERK1/2, while the com-
bination of R115777 ? 17AAG almost completely
blocked the phosphorylation of both Akt and ERK1/2
(Fig. 3d).
Discussion
In this paper, we provide evidence that 10 lM R115777
reduces viable cell number and induces apoptosis in U937
cells. The induction of apoptosis is shown by increased
activity of caspase-3 and increased amount of DNA nick-
ends (TUNEL). The increased cleavage of caspase-9 sug-
gests that 10 lM R115777 induces apoptosis by the
intrinsic pathway, which is in agreement with results
published earlier by other groups (Le Gouill et al. 2002;
Rolland et al. 2008). High concentrations of R115777 also
reduced the phosphorylation of Akt and ERK1/2, sug-
gesting the possible mechanistic explanation for efﬁcient
induction of apoptosis.
The main ﬁnding of our study is that the proapoptotic
activity of R115777 can be increased by using it in com-
bination with either LY294002 or 17AAG. The synergic
proapoptotic activity was demonstrated using individual
inhibitors at concentrations at which they acted mainly as
cytostatic agents, slowing down proliferation rate. Yet in
combination, they were able to exert cytotoxic effect
and truly diminish cell number. We have shown that
cytotoxicity of combinations R115777 ? LY294002 and
R115777 ? 17AAG was due to induction of apoptosis, as
seen by using TUNEL. Most importantly, the combination
of R115777 ? 17AAG showed synergic proapoptotic
activity at concentrations of individual inhibitors that are
certainly possible to achieve in human plasma after oral
administration at typical dosage (Zujewski et al. 2000; Karp
et al. 2001). This ﬁnding is of great importance, as both
compounds are registered anticancer drugs, which passed
clinical trials on humans, and hence, their combination
could be used in the near future to ﬁght certain hemato-
logical malignancies and possibly other types of cancer.
Weobservedthat10 lMR115777wasinducingapoptosis
inU937cellsand,atthesametime,was reducingthelevelof
phosphorylatedAktandERK1/2.Moreover,thecombination
of R115777 ? LY294002 reduced phosphorylation of Akt,
while the combination of R115777 ? 17AAG strongly
decreased the phosphorylation of both Akt and ERK1/2. It
seems therefore that in U937 cells, the ability of drugs and
Fig. 4 Combination of R115777 ? 17AAG reduces cell number and
induces apoptosis in U937 cells. a Cells were incubated for 24 h with
increasing concentrations of 17AAG and stained with trypan blue,
and the number of viable cells was counted. The amount of cells were
expressed as % of initial viable cell number (number of viable cells
present at the moment of 17AAG administration was set as 100%).
b Cells were incubated for 24 h in the absence or presence of
indicated concentrations of R115777, 17AAG or R115777 ? 17AAG
and stained with trypan blue, and the number of viable cells was
counted. The amount of viable cells were expressed as in (a). c Cells
were treated for 48 h in the absence or presence of indicated
concentrations of R115777, 17AAG or R115777 ? 17AAG. Next,
cells were ﬁxed and counted, and equal amount of cells were
subjected to TUNEL as in ‘‘Materials and methods.’’ The amount of
DNA nick-ends (A450nm) were expressed as fold increase relative to
control
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kinaseandtheMAPkinasesignalingpathwayscontributesto
increased efﬁciency of apoptosis induction.
The synergy between R115777 and LY294002 can be
logically explained. Since R115777 induces apoptosis via
the release of cytochrome c, the direct inhibition of PI3
kinase with LY294002 should decrease the activity of Akt
kinase and consequently block the whole prosurvival
pathway and help to unblock the apoptosis. The reasons
for the synergy between R115777 and 17AAG are prob-
ably more complex. Since Akt is an important client
protein for Hsp90, inhibition of Hsp90 by 17AAG should
decrease the activity of Akt, and the results in Fig. 3d
seem to support this rationale. However, there are a few
hundred client proteins for Hsp90, and it is actually dif-
ﬁcult to assign which target is the most important. For
example, survivin, which inhibits the activity of caspases,
is another client of Hsp90 (Zhao et al. 2005), and its
decreased activity would also help in unblocking apop-
tosis. Deﬁnitely, further research is required to better
explain the observed synergy between tipifarnib and
tanespimycin.
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